In addition, SYSUCC-002 trial showed the no-inferiority of trastuzumab and ET despite trastuzumab combined with CT as the first line of treatment in patients with HR-positive/HER2-positive metastatic BC [63]. The gene discussed is ERBB2; the disease is breast cancer.